-
Journal of Clinical Pharmacology Aug 1996A case involving a 27-year-old woman who ingested an overdose of acebutolol is presented. Extracorporeal membrane oxygenation was initiated to stabilize the patient's...
A case involving a 27-year-old woman who ingested an overdose of acebutolol is presented. Extracorporeal membrane oxygenation was initiated to stabilize the patient's condition before commencing hemodialysis. S-diacetolol (the N-acetelation product of acebutolol) was cleared with hemodialysis. It is suggested that extracorporeal membrane oxygenation may be of short-term benefit in the treatment of overdoses with beta-adrenergic agents such as acebutolol when accelerated clearance with hemodialysis is anticipated.
Topics: Acebutolol; Adrenergic beta-Antagonists; Adult; Drug Overdose; Extracorporeal Membrane Oxygenation; Female; Humans; Renal Dialysis
PubMed: 8877682
DOI: 10.1002/j.1552-4604.1996.tb04247.x -
American Heart Journal Feb 1986A double-blind multicenter study compared oral acebutolol (n = 182) with hydrochlorothiazide (n = 178) in the treatment of mild to moderate essential hypertension... (Clinical Trial)
Clinical Trial Comparative Study
A double-blind multicenter study compared oral acebutolol (n = 182) with hydrochlorothiazide (n = 178) in the treatment of mild to moderate essential hypertension (diastolic blood pressure 95 to 114 mm Hg). Both agents produced significant and comparable reductions in systolic, diastolic, and mean arterial blood pressures of 15.9, 14.9, and 15.3 mm Hg on acebutolol, and 15.2, 13.3, and 11.8 mm Hg on hydrochlorothiazide (p = 0.001). Acebutolol induced a significant reduction in resting heart rate of 9.3 bpm (p = 0.001) from baseline. The mean effective doses of acebutolol and hydrochlorothiazide were 757 and 68 mg, respectively. Significantly fewer patients on acebutolol experienced arrhythmia, anorexia, and flatulence, although an equal number of patients (14) in each group discontinued therapy prematurely due to side effects. More hydrochlorothiazide-treated patients developed abnormalities in the levels of serum glucose, uric acid, blood urea nitrogen (BUN), serum potassium, and chloride. No clinically significant trends in laboratory parameters were seen on acebutolol, although a small number of patients (11 on acebutolol and 3 on hydrochlorothiazide) developed asymptomatic positive antinuclear antibody (ANA) tests of low titer. The data show that acebutolol is as effective as hydrochlorothiazide in the treatment of hypertension, is as well tolerated, and produces fewer biochemical abnormalities.
Topics: Acebutolol; Adult; Aged; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Female; Heart Rate; Humans; Hydrochlorothiazide; Hypertension; Male; Middle Aged
PubMed: 3511650
DOI: 10.1016/0002-8703(86)90153-5 -
Cardiovascular Drugs and Therapy Jan 2001The aim of the study was to compare effect of perindopril (4 mg once a day) versus acebutolol (400 mg once a day) on cerebral hemodynamics in hypertensive patients. (Clinical Trial)
Clinical Trial Comparative Study Randomized Controlled Trial
PURPOSE
The aim of the study was to compare effect of perindopril (4 mg once a day) versus acebutolol (400 mg once a day) on cerebral hemodynamics in hypertensive patients.
METHODS
Thirty untreated patients with mild-to-moderate hypertension were studied. Drug influences on Doppler-derived parameters from the cerebral blood flow (CBF) velocity wave form were evaluated in a randomized, double blind, cross-over, placebo controlled study. The mean CBF velocity, pulsatility index (PI), cerebrovascular resistance and index of CBF were calculated from concomitant transcranial Doppler measurements and systemic blood pressure.
RESULTS
Acebutolol and perindopril significantly decreased systolic, diastolic and mean blood pressure in relation to placebo. The mean value of CBF velocity increased to a comparable level after both drugs (54.9 +/- 9.1 cm/s on placebo vs 62.8 +/- 14.5 cm/s on perindopril p<0.01 and 61.4 +/- 9.2 cm/s on acebutolol, p<0.01). Also, the cerebrovascular resistance index decreased similarly after both drugs (2.26 +/- 0.35 on placebo vs 1.68 +/- 0.42 on perindopril p<0.01 and 1.7 +/- 0.36 on acebutolol p<0.01). The calculated CBF index increased significantly after each drug (25.23 +/- 7.99 on placebo vs 33.98 +/- 11.23 p<0.01 on perindopril and 30.90 +/- 8.04 on acebutolol p<0.01). However, perindopril augmented the CBF index more effectively than acebutolol (p<0.05).
CONCLUSIONS
Among patients with mild-to-moderate hypertension both acebutolol and perindopril beneficially decreased cerebrovascular resistance and increased the CBF index in comparison with placebo. The increase of CBF index was greater after perindopril than acebutolol, which suggests a more significant improvement in cerebral perfusion by perindopril. The non-invasive transcranial Doppler ultrasonography method of CBF velocity measurement may contribute to choosing optimal antihypertensive therapies and to monitor their effect.
Topics: Acebutolol; Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Cerebrovascular Circulation; Cross-Over Studies; Double-Blind Method; Female; Humans; Hypertension; Male; Middle Aged; Perindopril; Ultrasonography, Doppler, Transcranial
PubMed: 11504165
DOI: 10.1023/a:1011114902880 -
The American Journal of Cardiology Nov 1983This study was designed to assess the relative antiarrhythmic activity of fixed doses of 2 beta-adrenergic blocking agents, propranolol and acebutolol, in a prospective... (Clinical Trial)
Clinical Trial Comparative Study Randomized Controlled Trial
This study was designed to assess the relative antiarrhythmic activity of fixed doses of 2 beta-adrenergic blocking agents, propranolol and acebutolol, in a prospective double-blind crossover trial. Twenty-one patients who had at least 30 premature ventricular contractions (PVCs) per hour while receiving placebo were entered into the study. Ten patients were randomized to initially receive propranolol, 40 mg every 8 hours, and 11 were assigned to receive acebutolol, 300 mg every 8 hours. After 6 weeks of treatment, patients were weaned off medication for 1 week and then placed on placebo for 1 week. Eighteen patients were available and eligible for crossover to the alternative regimen for an additional 6 weeks. All 21 patients completed courses with propranolol and 17 completed courses with acebutolol. The mean number of PVCs per hour during placebo, propranolol and acebutolol treatment were 267, 87 and 119, respectively. Using paired t test statistics on observation differences, both propranolol and acebutolol significantly reduced the number of PVCs per hour compared with placebo, whereas similar analysis revealed no significant difference in the antiarrhythmic effect. However, with the current sample size the power of the test is too low for the latter conclusion to be stated with confidence. Side effects were mild and infrequent, requiring discontinuation of acebutolol in 2 patients and discontinuation of propranolol in 1. Thus, acebutolol is a safe and effective antiarrhythmic agent and compares favorably with propranolol.
Topics: Acebutolol; Cardiac Complexes, Premature; Clinical Trials as Topic; Double-Blind Method; Electrocardiography; Female; Humans; Male; Monitoring, Physiologic; Propranolol; Prospective Studies; Random Allocation
PubMed: 6195911
DOI: 10.1016/0002-9149(83)90518-0 -
British Journal of Clinical Pharmacology Apr 19821 The effect of acebutolol, a relatively selective beta-adrenoceptor blocking drug and propranolol, a non-selective one, on the hypoglycaemic action of glibenclamide...
1 The effect of acebutolol, a relatively selective beta-adrenoceptor blocking drug and propranolol, a non-selective one, on the hypoglycaemic action of glibenclamide after an oral glucose load has been investigated in a group of maturity-onset diabetic patients. 2 Glibenclamide significantly reduced the blood glucose levels and both acebutolol and propranolol, at therapeutic doses, were found to modify this action significantly. 3 The effect of acebutolol was slightly less than that of propranolol. The difference was not statistically significant. 4 The modes of action of sulphonylureas are reviewed and it is suggested that beta-adrenoceptor blockers may modify their effect on insulin release. This appears to be a drug interaction rather than an effect of beta-adrenoceptor blockade on glucose tolerance.
Topics: Acebutolol; Adult; Aged; Blood Glucose; Diabetes Mellitus; Drug Interactions; Female; Glyburide; Humans; Male; Middle Aged; Propranolol; Time Factors
PubMed: 6802160
DOI: 10.1111/j.1365-2125.1982.tb01412.x -
Ceska Gynekologie Jan 2002The main purpose of our study was to analyse efficacy and safety of acebutolol (Sectral) in the treatment of hypertension in pregnancy. (Clinical Trial)
Clinical Trial Comparative Study
OBJECTIVE
The main purpose of our study was to analyse efficacy and safety of acebutolol (Sectral) in the treatment of hypertension in pregnancy.
DESIGN
Cohort clinical study comparing efficacy and safety of acebutolol with other antihypertensive drugs by 77 patients and their 81 newborns. The number of 48 patients were treated by acebutolol.
SETTING
Internal Medicine and Clinical Pharmacology Department, Regional Hospital, Nitra and The Faculty of Health Service and Social Work, University of Trnava; Department of Gynaecology and Obstetrics, Regional Hospital Nitra and The Faculty of Health Service and Social Work, University of Trnava; Institute of Pharmacology, The Faculty of Medicine, Komenského University, Bratislava; Environment, a.s. Nitra.
METHODS
During the period of 6 years our patients were divided into subgroups according to the type of hypertension in pregnancy and the severity of the illness which was the basis for used antihypertensive drugs. One of the topics of the study was to provide monitoring of adverse events by mother and possible drug influence on their new-born has been evaluated by investigating the week of birth, weight and length of the new-born and evaluating of Apgar score.
RESULTS
In the subgroup of 48 women treated by acebutolol we have confirmed the efficacy and safety of this antihypertensive drug without any clinically significant effect on the quality of life of their new-born and evaluating of Apgar score.
CONCLUSION
With regard to the results of our clinical study we can consider acebutolol to be effective and safe antihypertensive drug in the treatment of hypertension in pregnancy.
Topics: Acebutolol; Adolescent; Adult; Antihypertensive Agents; Female; Humans; Hypertension; Pregnancy; Pregnancy Complications, Cardiovascular
PubMed: 11881282
DOI: No ID Found -
Annals of Internal Medicine Sep 1989
Topics: Acebutolol; Adult; Chemical and Drug Induced Liver Injury; Female; Humans; Liver Diseases; Liver Function Tests; Male; Middle Aged; Recurrence; United States; United States Food and Drug Administration
PubMed: 2774374
DOI: 10.7326/0003-4819-111-6-533 -
Deutsche Medizinische Wochenschrift... Nov 1985
Topics: Acebutolol; Flunitrazepam; Humans; Male; Middle Aged; Suicide
PubMed: 4054007
DOI: No ID Found -
The Journal of International Medical... 1979Twenty-one essential hypertensives were randomly treated with Aldactone, acebutolol or a combination of the two drugs. Statistically significant falls in systolic and... (Clinical Trial)
Clinical Trial Comparative Study Randomized Controlled Trial
Twenty-one essential hypertensives were randomly treated with Aldactone, acebutolol or a combination of the two drugs. Statistically significant falls in systolic and diastolic pressures were demonstrated during treatment with Aldactone 100 mg daily, also when acebutolol and Aldactone 200 mg daily were administered. When the combination of Aldactone and acebutolol was given, diastolic pressures were lowered to a greater degree than seen with individual treatments.
Topics: Acebutolol; Adult; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Hypertension; Male; Middle Aged; Placebos; Spironolactone
PubMed: 369923
DOI: 10.1177/030006057900700104 -
Journal of AOAC International 2015Two therapeutically active compounds from the group of β-blockers, acebutolol (AC) and alprenolol (AL), in solid form were subjected to ionizing radiation emitted by a...
Two therapeutically active compounds from the group of β-blockers, acebutolol (AC) and alprenolol (AL), in solid form were subjected to ionizing radiation emitted by a beam of high energy electrons from an accelerator with a standard sterilization dose of 25 kGy and in higher doses of 50-400 kGy. The effects of irradiation were detected by chromatographic methods (TLC, HPLC) and a hyphenated method (HPLC/MS/MS). No significant changes in the physicochemical properties of both compounds studied irradiated with 25 kGy were noted, but upon irradiation with the highest dose (400 kGy) the loss of AC and AL content determined by HPLC was 2.79 and 9.12%, respectively. The product of AC decomposition and the two products of AL decomposition were separated and identified by HPLC/MS/MS. It has been established that radiodegradation of AC and AL takes place by oxidation, leading to formation of the products of radiolysis, most probably alcohol derivatives of the β-blockers studied. The additional product that appears on radiodegradation of AL is probably formed as a result of two simultaneous reactions: oxidation and CH2 group elimination.
Topics: Acebutolol; Alprenolol; Chromatography, High Pressure Liquid; Radiation, Ionizing; Tandem Mass Spectrometry
PubMed: 25857877
DOI: 10.5740/jaoacint.14-096